Data on biological therapies for ISCMs come mainly from three options that have been tested in the treatment of ISCMs-LC: targeted epidermal growth factor receptor (EGFR) mutants (13, 27), anaplastic lymphoma kinase (ALK) (28), and immune checkpoint inhibitors (ICIs) (29). This evidence concerns the gene ALK and laryngotracheoesophageal cleft.